<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ten patients developing <z:hpo ids='HP_0002665'>lymphomas</z:hpo> after disease modifying <z:chebi fb="0" ids="35842">anti-rheumatic drugs</z:chebi> (DMARD) (<z:chebi fb="0" ids="44185">methotrexate</z:chebi>, n = 3, mean cumulative dose = 3.4 g; <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, n = 2, mean dose = 70 g; <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, n = 6, mean dose = 243 g) were investigated </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="44185">Methotrexate</z:chebi>-related <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were Epstein-Barr virus (EBV)-positive, had infrequent aberrant methylation of p15 and p16, and responded well to <z:chebi fb="0" ids="44185">methotrexate</z:chebi> withdrawal or anti-CD20 antibody (rituximab) alone without concomitant chemotherapy, implying that defective immunosurveillance was important in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, 75% of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/<z:chebi fb="2" ids="2948">azathioprine</z:chebi>-related <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were EBV-negative, had frequent p15 and p16 methylation, and responded poorly to <z:e sem="disease" ids="C0152128" disease_type="Disease or Syndrome" abbrv="">drug withdrawal</z:e> and chemotherapy, implying that direct drug-induced mutagenesis might be involved in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
</text></document>